Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mitomycin · Jelmyto, Mitosol

Small molecule · developed by Supergen

Approved FDA, Nov 2002
7 Registered trials

What is Mitomycin?

Mitomycin is an antineoplastic antibiotic that alkylates DNA, producing interstrand cross-links that inhibit DNA synthesis; at high concentrations it also suppresses RNA and protein synthesis. It is studied in urothelial carcinoma of the upper urinary tract and bladder, delivered locally via pyelocalyceal solution, intravesical administration, or a sustained-release hydrogel formulation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Jelmyto, Mitosol, Mitozytrex, Zusduri, UGN-102, UGN-101, NSC-26980, MitoGel
Drug type
Small molecule
Pathways
DNA synthesis inhibition, RNA and protein synthesis suppression at high concentrations
Therapy area
Oncology
Developer
Supergen
In trials of
HALO, PFE, URGN
FDA status
Approved as Jelmyto, Mitosol, Mitozytrex (November 14, 2002), NDA050763 · FDA label
UNII
50SG953SK6

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 9, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05243550 Phase 3 Bladder Cancer Active not recruiting URGN
NCT02793128 Phase 3 Carcinoma, Transitional Cell Completed URGN
NCT02307487 Phase 2 Bladder Cancer Completed URGN
NCT00318643 Phase 1/2 Bladder Cancer Completed HALO
NCT05874921 N/A Urothelial Carcinoma Recruiting URGN
NCT02701023 N/A Urothelial Carcinoma Ureteral Location No longer available URGN
NCT05494411 N/A Urothelial Cancer of Renal Pelvis Available URGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Urothelial CarcinomaUrothelial Carcinoma BladderBladder CancerCarcinoma, Transitional CellNeoplasmsTransitional Cell Carcinoma of Renal PelvisUrinary Bladder DiseasesUrologic DiseasesUrothelial Cancer of Renal PelvisUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma RecurrentUrothelial Carcinoma UreterUrothelial Carcinoma Ureter RecurrentUrothelial Carcinoma Ureteral Location

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.